文献速递免疫规划妇幼与学校卫生卫生政策与健康促进

孕期RSVpreF疫苗接种率与社会经济、产检利用及母亲风险因素的关联

Uptake of the RSVpreF vaccine during pregnancy: associations with socioeconomic status, prenatal care utilization, and maternal risk factors.
PubMed 文献 · Vaccine · 2026-08-13

多因素模型显示较高接种率与年龄、收入、学历、PPO保险、既往流感疫苗及孕期流感/Tdap接种、产检服务利用相关,合并症无关联。

要点

  • 首个RSV流行季孕妇RSVpreF接种率仅14.5%,随分娩月份推移上升。
  • 接种率与社会经济地位、其他疫苗接种及产检服务利用显著相关。
  • 需针对差异开展公平可及性与教育干预以提升母亲免疫规划效果。

核心结论

  • 母亲RSVpreF疫苗首个上市流行季接种率低,且社会人口学因素、其他疫苗接种及产检依从性存在显著差异。

主要发现

  • 14121名孕妇中14.5%接种RSVpreF疫苗。
  • 84.6%的接种者在推荐32-36周孕周窗口内接种。
  • 多因素模型中,年龄30-39岁 vs 18-29岁OR=1.52(95%CI:1.28-1.80),家庭收入$60,000-$74,000 OR=1.40(95%CI:1.05-1.85)、$75,000-$99,000 OR=1.47(95%CI:1.13-1.92),本科及以上OR=1.70(95%CI:1.48-1.96),PPO保险OR=2.87(95%CI:1.70-4.87)。
  • 既往流感疫苗接种OR=1.78(95%CI:1.56-2.04),孕期接种流感疫苗OR=3.65(95%CI:3.14-4.24)、接种Tdap疫苗OR=4.40(95%CI:3.53-5.49),RSVpreF接种窗口每增加一周OR=1.27(95%CI:1.06-1.53),完成≥5/7项非疫苗产检服务OR=1.82(95%CI:1.23-2.70);合并症与接种无关联。

临床怎么用

  • 应关注低社会经济地位、未接种其他疫苗及产检利用不足的孕妇,针对性开展RSVpreF疫苗教育与可及性干预。

局限性

  • 研究仅纳入商业保险且具备社会经济记录的孕妇,结果外推至无保险或医疗补助人群受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Respiratory syncytial virus (RSV) is a leading cause of infant respiratory illness. In August 2023, the RSV protein-based vaccine (RSVpreF) became the first maternal vaccine approved in the United States to prevent RSV infection in newborns. The study aims to estimate RSVpreF vaccine uptake during its first RSV season and to identify key factors associated with uptake among commercially insured pregnant individuals, using Optum's de-identified Clinformatics® Data Mart Database. The study included individuals aged 18-50 with live birth deliveries at or after 32 weeks' gestation between October 1, 2023, and January 31, 2024, continuous enrollment from July 1, 2022, through delivery, and available socioeconomic records. Among 14,121 pregnant individuals,14.5% received the RSVpreF vaccine. Uptake rose from 1.5% among the October 2023 delivery cohort to 28.7% among the January 2024 cohort; 84.6% were vaccinated within the recommended 32-36 week gestational window. In multivariable models, higher uptake was associated with age (30-39 vs 18-29 years: OR = 1.52, 95% CI: 1.28-1.80), household income $60,000-$74,000 (OR = 1.40, 95% CI: 1.05-1.85) or $75,000-$99,000 (OR = 1.47, 95% CI: 1.13-1.92), bachelor's degree or higher (OR = 1.70, 95% CI: 1.48-1.96), PPO insurance (OR = 2.87, 95% CI: 1.70-4.87), prior influenza vaccination (OR = 1.78, 95% CI: 1.56-2.04), receipt of influenza (OR = 3.65, 95% CI: 3.14-4.24) or Tdap (OR = 4.40, 95% CI: 3.53-5.49) vaccines during pregnancy, and each additional week in the RSVpreF vaccination window(OR = 1.27; 95% CI: 1.06-1.53). Receiving ≥5 of 7 non-vaccine prenatal care services was also associated with higher uptake (OR = 1.82, 95% CI: 1.23-2.70). Comorbidities were not associated with uptake. Maternal RSVpreF vaccine uptake was low during its first on-market season, with significant disparities by sociodemographic factors, uptake of other vaccines, and adherence to recommended prenatal care. Efforts to improve equitable access and education are needed for effective maternal immunization programs.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Liu X, Cloughesy JN, Yu T, et al. Uptake of the RSVpreF vaccine during pregnancy: associations with socioeconomic status, prenatal care utilization, and maternal risk factors. Vaccine. 2026. PMID: 42594641. doi:10.1016/j.vaccine.2026.129003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。